Herpes simplex viral-vector design for efficient transduction of nonneuronal cells without cytotoxicity

The design of highly defective herpes simplex virus (HSV) vectors for transgene expression in nonneuronal cells in the absence of toxic viral-gene activity has been elusive. Here, we report that elements of the latency locus protect a nonviral promoter against silencing in primary human cells in the...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 112; no. 13; pp. E1632 - E1641
Main Authors Miyagawa, Yoshitaka, Marino, Pietro, Verlengia, Gianluca, Uchida, Hiroaki, Goins, William F., Yokota, Shinichiro, Geller, David A., Yoshida, Osamu, Mester, Joseph, Cohen, Justus B., Glorioso, Joseph C.
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 31.03.2015
National Acad Sciences
SeriesPNAS Plus
Subjects
Online AccessGet full text
ISSN0027-8424
1091-6490
1091-6490
DOI10.1073/pnas.1423556112

Cover

More Information
Summary:The design of highly defective herpes simplex virus (HSV) vectors for transgene expression in nonneuronal cells in the absence of toxic viral-gene activity has been elusive. Here, we report that elements of the latency locus protect a nonviral promoter against silencing in primary human cells in the absence of any viral-gene expression. We identified a CTCF motif cluster 5′ to the latency promoter and a known long-term regulatory region as important elements for vigorous transgene expression from a vector that is functionally deleted for all five immediate-early genes and the 15-kb internal repeat region. We inserted a 16.5-kb expression cassette for full-length mouse dystrophin and report robust and durable expression in dystrophin-deficient muscle cells in vitro. Given the broad cell tropism of HSV, our design provides a nontoxic vector that can accommodate large transgene constructs for transduction of a wide variety of cells without vector integration, thereby filling an important void in the current arsenal of genetherapy vectors.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
Author contributions: Y.M., J.B.C., and J.C.G. designed research; Y.M., P.M., G.V., H.U., W.F.G., S.Y., O.Y., and J.M. performed research; D.A.G. contributed new reagents/analytic tools; Y.M., J.B.C., and J.C.G. analyzed data; and Y.M., J.B.C., and J.C.G. wrote the paper.
Edited by Kenneth I. Berns, University of Florida College of Medicine, Gainesville, FL, and approved February 24, 2015 (received for review December 10, 2014)
1Present address: Division of Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
ISSN:0027-8424
1091-6490
1091-6490
DOI:10.1073/pnas.1423556112